nCoV: Rapid Clinical Development of ChAdOx1 nCoV-19

点击翻译按钮获取中文摘要

ChAdOx1 is a safe and effective vaccine vector that can be used to produce vaccinesagainst many different diseases. Unlike other rapid vaccine technologies, only a singledose of the vaccine is likely to be needed. DNA, mRNA and recombinant protein vaccinestypically require two or three doses to achieve protective immunity. ChAdOx1 has beenused to make a Middle East Respiratory Syndrome Coronavirus vaccine which isprotective in non-human primates after a single dose, and is safe and highly immunogenicin humans as demonstrated in a phase I clinical trial. The same vaccine design has beenfollowed to produce ChAdOx1 nCoV. We now propose to manufacture this vaccine tocGMP and conduct a clinical trial in healthy volunteers in the UK. We will work closely withthe MHRA to complete all required testing of the vaccine and obtain regulatory approval inas short a time as possible, with the aim of initiaiting the clinical trial in June.We will also work with partners to demonstrate protective efficacy of ChAdOx1 nCoV intwo different animal models. This will provide the necessary information to support furtherclinical trials of this vaccine to demonstrate efficacy in humans.